Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

BUFFALO, NY - March 21, 2025 – A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled “ No disease ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

The KATHERINE trial included 1,486 patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer who had residual invasive disease in the breast or axillary lymph node ...

"Residual cancer is identified on histology in 40% of lung, 57–69% of renal cell, 7.7–47.6% of prostate and 0–86.7% of hepatocellular carcinoma." ...

Background: Variable rates of HER2 protein overexpression and gene ... they had measurable lesions (n = 4) or elevated cancer antigen 125 level and non-measurable lesions (n = 3).

Trastuzumab works by binding to HER2 proteins that are found on the cells of HER2-positive breast cancer. By binding to those proteins, it helps deliver the chemotherapy drug to the targeted tumor ...

AUSTIN, Texas, March 10, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the ...